DURECT Corporation (DRRX) earnings
DRRX earnings moved a median of -5.60% by the close. Quarterly and annual DRRX reports and results, each read against the price at its own news timestamp. Back to the DRRX overview →
18 measured DRRX earnings events.
Where these DRRX earnings landedvs 18 measured DRRX earnings reactions
| Middle 50% of DRRX earnings reactions | -11.50% to +0.93% |
|---|---|
| Median reaction (to close) | -5.60% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 DRRX earnings events with a measured close landed between -11.50% and +0.93%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q DURECT CORP For: Jun 30 | SEC filing · Form 10-Q | +0.53% | +0.53% | |
| DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health | Press release | +0.53% | +1.06% | |
| Form 10-Q DURECT CORP For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -11.39% | |
| DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -10.44% | -20.94% | |
| Form 10-K DURECT CORP For: Dec 31 | SEC filing · Form 10-K | +1.13% | -0.74% | |
| Form 10-Q DURECT CORP For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -9.82% | |
| DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -10.21% | -14.50% | |
| DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update | Press release | +0.00% | -2.90% | |
| Form 10-Q DURECT CORP For: Jun 30 | SEC filing · Form 10-Q | -3.70% | -14.81% | |
| DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update | Press release | +0.00% | -7.64% | |
| DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update | Press release | +2.22% | +8.89% | |
| Form 10-Q DURECT CORP For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +5.50% | |
| DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update | Press release | -11.85% | -11.54% | |
| DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update | Press release | +0.00% | -15.00% | |
| Form 10-K DURECT CORP For: Dec 31 | SEC filing · Form 10-K | -2.44% | -9.76% | |
| Form 10-Q DURECT CORP For: Sep 30 | SEC filing · Form 10-Q | +1.88% | +14.58% | |
| DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update | Press release | +1.82% | +4.42% | |
| DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update | Press release | -1.82% | -3.56% |
Keep exploring
More DRRX: analyst actions → · SEC filings → · DRRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AVITA MEDICAL (AVMXY) | 160 | 0.00% | 46% |
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | 159 | -1.17% | 27% |
| Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) | 159 | -1.80% | 36% |
| GT Biopharma, Inc. (GTBP) | 159 | -0.91% | 32% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.